- QIAGEN’s Q3 2024 net sales rose 5% to $502 million, exceeding expectations.
- Adjusted EPS increased to $0.57, surpassing the outlook.
- Diagnostic solutions led with 10% growth. Free cash flow grew 73% in 2024’s first nine months.
Wed Nov 06 22:10:11 -0000 2024 UTC– QIAGEN reports strong growth in Q3 2024, exceeding expectations. Net sales reached $502 million with a 6% increase in constant exchange rates.
Adjusted EPS was $0.57, surpassing the outlook of at least $0.55.
The company’s performance was driven by a 10% growth in Diagnostic solutions and increased operating income margin.
QIAGEN reaffirmed its full-year 2024 sales outlook and raised adjusted EPS outlook to at least $2.19 CER.
The company raised its full-year adjusted EPS outlook to at least $2.19. CEO Thierry Bernard highlighted strong sales trends and a resilient portfolio. Recent developments include new assays for the QIAcuity system and partnerships with AstraZeneca and Eli Lilly.
CFO Roland Sackers emphasized initiatives for increased efficiency and profitability by 2028.